<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102140</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVEHF</org_study_id>
    <nct_id>NCT01102140</nct_id>
  </id_info>
  <brief_title>The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study</brief_title>
  <acronym>ImPrOVE</acronym>
  <official_title>The Impact of Pomegranate (Punica Granatum) Polyphenol Extract on Oxidative Stress, Ventricular Remodeling and Endothelial Function in Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Cowger , MD, MS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>POM Wonderful LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This blinded, controlled study will examine the impact of pomegranate polyphenol extract
      (POMx, from Pom Wonderful, LLC), 1000mg on cardiomyopathy in subjects with chronic renal
      insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is a disease of great prevalence in the U.S. with an associated high
      morbidity and mortality. In individuals with concomitant chronic renal insufficiency (CRI),
      outcomes are even worse due to pharmaceutical under treatment and higher baseline levels of
      oxidative stress. Reactive oxygen species (ROS) are generated during mechanoenergetic
      uncoupling and can cause myocardial protein, lipid, and DNA damage, leading to the
      development of HF. One means of preventing the progression of HF may be through ROS reduction
      or an improvement in systemic or local oxidative stress handling. In this randomized, single
      blind placebo-controlled pilot study, we hypothesize that 12 weeks of treatment with oral
      pomegranate extract (POMx) will lead to a reduction in oxidative stress (as assessed by
      measuring thiobarbituric acid-reactive substances, F8-isoprostanes, and glutathione) in
      subjects (n=30) with cardiomyopathy (LVEF ≤40%) and CRI (GFR &lt;60 ml/hr). Secondary aims
      include assessing the impact of POMx on myocardial remodeling and endothelial dysfunction by
      measuring serum collagen levels and asymmetric dimethylarginine, respectively. Findings from
      this study will serve as pilot data for a larger randomized trial of longer term POMx therapy
      in subjects with cardiomyopathy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left University of Michigan
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 31, 2013</completion_date>
  <primary_completion_date type="Actual">May 31, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The participant will either receive POMx or matching placebo (sugar pill)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Thiobarbituric Reactive Substances (TBARS)</measure>
    <time_frame>baseline and after 12 weeks</time_frame>
    <description>This is a serum marker of oxidative stress.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>F-8 Isoprostanes</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>This is a serum marker of oxidative stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procollagen Types I (PINP) and III (PIIINP)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>This is a serum marker of collagen turnover (fibrosis/scar formation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymmetric Dimethylarginine (ADMA)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>ADMA is a serum enzyme involved in metabolism of endothelium derived nitric oxide (NO). NO's has an important role in maintaining endothelial homeostasis. Elevated ADMA levels suggest impaired endothelial function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cardiomyopathy</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>POMx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 subjects will received 1000 mg of oral POMx for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control- sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 subjects will receive a matching sugar pill for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>POMx, pomegranate polyphenol extract</intervention_name>
    <description>1000 mg orally once daily.</description>
    <arm_group_label>POMx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>Matching sugar pill</description>
    <arm_group_label>Control- sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (≥21 years of age) with cardiomyopathy (ejection fraction ≤40%) of at
             least 1 year duration and CRI (GFR &lt;60 cc/hr for at least 3 months) will be eligible
             for enrollment.

          -  Subjects must have New York Heart Association (NYHA) functional class I-III symptoms
             and be on stable doses of HF evidence-based therapies (β-blocker, ACE inhibitor or
             ARBs, aldosterone inhibitor [if appropriate]) for at least 3 months or have a
             documented contraindication or intolerance to such therapy

        Exclusion Criteria:

          -  Subjects admitted to a hospital for acute myocardial infarction (defined as positive
             troponins) or HF exacerbation within the last 6 months will not be eligible for
             enrollment.

          -  Subjects on warfarin or rosuvastatin will also be excluded.

          -  Other exclusion criteria are as follows:

               -  HF that is deemed to be congenital or infiltrative in etiology

               -  the presence of a life-threatening illness with a projected survival ≤6 months;
                  ongoing infection

               -  pregnancy

               -  inability to follow-up

               -  end-stage renal disease requiring dialysis

               -  renal transplant listing

               -  recent (within last 6 months) POMx use or intake &gt;8 ounces daily of pomegranate
                  juice

               -  known hypersensitivity to any fruit in the Punicaceae family

               -  connective tissue or collagen vascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer C Matthews, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Michigan Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertram Pitt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <results_first_submitted>May 18, 2017</results_first_submitted>
  <results_first_submitted_qc>June 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2017</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Jennifer Cowger , MD, MS</investigator_full_name>
    <investigator_title>Assistant Professor, study PI</investigator_title>
  </responsible_party>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>POMx</title>
          <description>The POMx subjects received 1000 mg of oral POMx for 12 weeks.
POMx, pomegranate polyphenol extract: 1000 mg orally once daily.</description>
        </group>
        <group group_id="P2">
          <title>Control- Sugar Pill</title>
          <description>The control subjects received a matching sugar pill for 12 weeks.
Sugar Pill: Matching sugar pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator terminated study</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>POMx</title>
          <description>The POMx subjects received 1000 mg of oral POMx for 12 weeks.
POMx, pomegranate polyphenol extract: 1000 mg orally once daily.</description>
        </group>
        <group group_id="B2">
          <title>Control- Sugar Pill</title>
          <description>The control subjects received a matching sugar pill for 12 weeks.
Sugar Pill: Matching sugar pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="49" upper_limit="64"/>
                    <measurement group_id="B2" value="58" lower_limit="52" upper_limit="64"/>
                    <measurement group_id="B3" value="57" lower_limit="50" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thiobarbituric Reactive Substances (TBARS)</title>
        <description>This is a serum marker of oxidative stress.</description>
        <time_frame>baseline and after 12 weeks</time_frame>
        <population>Serum samples were obtained and frozen but never analyzed to obtain isoprostane values due to PI departure from study center prior to any batches being sent for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>POMx</title>
            <description>The POMx subjects received 1000 mg of oral POMx for 12 weeks.
POMx, pomegranate polyphenol extract: 1000 mg orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Control- Sugar Pill</title>
            <description>The control subjects received a matching sugar pill for 12 weeks.
Sugar Pill: Matching sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Thiobarbituric Reactive Substances (TBARS)</title>
          <description>This is a serum marker of oxidative stress.</description>
          <population>Serum samples were obtained and frozen but never analyzed to obtain isoprostane values due to PI departure from study center prior to any batches being sent for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>F-8 Isoprostanes</title>
        <description>This is a serum marker of oxidative stress.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Serum samples were obtained and frozen but never analyzed to obtain isoprostane values due to PI departure from study center prior to any batches being sent for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>POMx</title>
            <description>The POMx subjects received 1000 mg of oral POMx for 12 weeks.
POMx, pomegranate polyphenol extract: 1000 mg orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Control- Sugar Pill</title>
            <description>The control subjects received a matching sugar pill for 12 weeks.
Sugar Pill: Matching sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>F-8 Isoprostanes</title>
          <description>This is a serum marker of oxidative stress.</description>
          <population>Serum samples were obtained and frozen but never analyzed to obtain isoprostane values due to PI departure from study center prior to any batches being sent for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procollagen Types I (PINP) and III (PIIINP)</title>
        <description>This is a serum marker of collagen turnover (fibrosis/scar formation).</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Serum samples were obtained and frozen but never analyzed to obtain procollagen values due to PI departure from study center prior to any batches being sent for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>POMx</title>
            <description>The POMx subjects will receive 1000 mg of oral POMx for 12 weeks.
POMx, pomegranate polyphenol extract: 1000 mg orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Control- Sugar Pill</title>
            <description>The control subjects received a matching sugar pill for 12 weeks.
Sugar Pill: Matching sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Procollagen Types I (PINP) and III (PIIINP)</title>
          <description>This is a serum marker of collagen turnover (fibrosis/scar formation).</description>
          <population>Serum samples were obtained and frozen but never analyzed to obtain procollagen values due to PI departure from study center prior to any batches being sent for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asymmetric Dimethylarginine (ADMA)</title>
        <description>ADMA is a serum enzyme involved in metabolism of endothelium derived nitric oxide (NO). NO's has an important role in maintaining endothelial homeostasis. Elevated ADMA levels suggest impaired endothelial function.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Serum samples were obtained and frozen but never analyzed to obtain ADMA values due to PI departure from study center prior to any batches being sent for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>POMx</title>
            <description>The POMx subjects received 1000 mg of oral POMx for 12 weeks.
POMx, pomegranate polyphenol extract: 1000 mg orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Control- Sugar Pill</title>
            <description>The control subjects received a matching sugar pill for 12 weeks. Sugar Pill: Matching sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Asymmetric Dimethylarginine (ADMA)</title>
          <description>ADMA is a serum enzyme involved in metabolism of endothelium derived nitric oxide (NO). NO's has an important role in maintaining endothelial homeostasis. Elevated ADMA levels suggest impaired endothelial function.</description>
          <population>Serum samples were obtained and frozen but never analyzed to obtain ADMA values due to PI departure from study center prior to any batches being sent for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>POMx</title>
          <description>15 subjects received 1000 mg of oral POMx for 12 weeks.
POMx, pomegranate polyphenol extract: 1000 mg orally once daily.</description>
        </group>
        <group group_id="E2">
          <title>Control- Sugar Pill</title>
          <description>The control subjects received a matching sugar pill for 12 weeks.
Sugar Pill: Matching sugar pill</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Cowger</name_or_title>
      <organization>University of Michigan</organization>
      <phone>7345464911</phone>
      <email>jennifercowger@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

